expert consensus

专家共识
  • 文章类型: Journal Article
    经鼻加湿快速吹气换气(THRIVE)是一种安全的,有效,以及目前用于电惊厥治疗(ECT)的新技术。本研究旨在总结在ECT中使用THRIVE的临床实践,以帮助医生和机构实施ECT的最佳实践指南。因此,我们回顾了目前的文献,并就THRIVE在ECT的日常临床实践中的应用提出了共识.该共识提供了有关ECT中使用THRIVE的信息,包括它的安全性,有效性,程序,预防措施,特殊案件管理,以及在特殊人群中的应用。此外,它指导ECT中THRIVE的标准化使用。
    Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) is a safe, effective, and novel technique that is currently being used in electroconvulsive therapy (ECT). This study aimed to summarize the clinical practices of THRIVE use in ECT to aid physicians and institutions in implementing the best practice guidelines for ECT. Thus, we reviewed the current literature and presented our consensus on the application of THRIVE in ECT in daily clinical practice. This consensus provides information regarding THRIVE use in ECT, including its safety, effectiveness, procedures, precautions, special case management, and application in special populations. Moreover, it guides the standardized use of THRIVE in ECT.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:回顾不同物理治疗对急性和亚急性下腰痛的有效性,并为物理治疗师制定临床处方的临床建议和专家共识。
    方法:在PubMed和Cochrane图书馆进行了系统搜索,以查找在过去15年中发表的研究。
    方法:系统评价和荟萃分析,纳入了评估急性和亚急性下腰痛患者的随机对照试验.两名评审员使用相同的纳入标准独立筛选相关研究。使用物理治疗证据数据库和多重系统评价工具对随机对照试验和系统评价的质量评价进行分级。分别。最终的推荐等级是基于22名国际专家的德尔菲共识讨论结果。
    结果:纳入21项系统评价和21项随机对照试验。对于急性下腰痛,建议使用脊柱手法治疗和低水平激光治疗。核心稳定性练习/电机控制,脊椎手法治疗,按摩可用于治疗亚急性下腰痛。
    结论:共识声明为医务人员提供了适用于急性和亚急性下腰痛的物理治疗建议。这份共识声明需要在5-10年后定期更新。
    OBJECTIVE: To review the effectiveness of different physical therapies for acute and sub-acute low back pain supported by evidence, and create clinical recommendations and expert consensus for physiotherapists on clinical prescriptions.
    METHODS: A systematic search was conducted in PubMed and the Cochrane Library for studies published within the previous 15 years.
    METHODS: Systematic review and meta-analysis, randomized controlled trials assessing patients with acute and sub-acute low back pain were included. Two reviewers independently screened relevant studies using the same inclusion criteria. The Physiotherapy Evidence Database and the Assessment of Multiple Systematic Reviews tool were used to grade the quality assessment of randomized controlled trials and systematic reviews, respectively. The final recommendation grades were based on the consensus discussion results of the Delphi of 22 international experts.
    RESULTS: Twenty-one systematic reviews and 21 randomized controlled trials were included. Spinal manipulative therapy and low-level laser therapy are recommended for acute low back pain. Core stability exercise/motor control, spinal manipulative therapy, and massage can be used to treat sub-acute low back pain.
    CONCLUSIONS: The consensus statements provided medical staff with appliable recommendations of physical therapy for acute and sub-acute low back pain. This consensus statement will require regular updates after 5-10 years.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    后上肩袖撕裂是肩部不适的最常见原因之一。虽然非手术治疗通常是针对功能需求低的老年患者,手术治疗被认为是活跃患者的金标准。更确切地说,解剖肩袖修复(RCR)被认为是最理想的治疗选择,一般应在手术过程中尝试.如果解剖RCR是不可能的,对于不可修复的肩袖撕裂,选择适当的治疗方法仍是肩关节外科医师争论的问题.在对当代文学进行批判性审查之后,作者提出了以下基于证据和经验的治疗建议.在非功能性的,骨关节炎肩,治疗不可修复的后上RCT的治疗策略包括基于清创术的手术和逆向全肩关节置换术作为治疗的选择.非骨关节炎的肩关节应保留旨在恢复肱骨生物力学和功能的关节保留程序。在这些程序之前,然而,随着时间的推移,应该向患者提供恶化结果的建议。最近的创新,如优越的囊重建和肩峰下间隔物的植入显示有希望的短期结果,然而,未来的研究需要长期随访,以得出更强有力的建议。
    Posterosuperior rotator cuff tears range among the most common causes of shoulder complaints. While non-operative treatment is typically reserved for the elderly patient with low functional demands, surgical treatment is considered the gold standard for active patients. More precisely, an anatomic rotator cuff repair (RCR) is considered the most desirable treatment option and should be generally attempted during surgery. If an anatomic RCR is impossible, the adequate choice of treatment for irreparable rotator cuff tears remains a matter of debate among shoulder surgeons. Following a critical review of the contemporary literature, the authors suggest the following evidence- and experience-based treatment recommendation. In the non-functional, osteoarthritic shoulder, treatment strategies in the management of irreparable posterosuperior RCT include debridement-based procedures and reverse total shoulder arthroplasty as the treatment of choice. Joint-preserving procedures aimed at restoring glenohumeral biomechanics and function should be reserved for the non-osteoarthritic shoulder. Prior to these procedures, however, patients should be counseled about deteriorating results over time. Recent innovations such as the superior capsule reconstruction and the implantation of a subacromial spacer show promising short-term results, yet future studies with long-term follow-up are required to derive stronger recommendations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:伴有C1抑制剂缺乏症的遗传性血管性水肿(HAE-C1INH)是一种以肿胀发作为特征的罕见疾病。它影响生活质量(QoL)并且可能致命,当涉及上呼吸道时。治疗是个性化的,治疗方案包括按需治疗(ODT),以及短期和长期预防(STP,LTP)。然而,可用的指南并不总是明确的治疗选择,其目标或目标成就的评估。
    目的:审查HAE-C1INH管理的现有证据,并建立西班牙专家共识,以指导HAE-C1INH管理朝着治疗目标(T2T)方法发展,同时解决了西班牙指南中一些不清楚的方面。
    方法:我们回顾了用T2T方法管理HAE-C1INH的文献,重点关注:1)治疗选择和目标;2)评估目标成就的可用工具。我们根据临床经验讨论了文献,并就未定义的管理方面起草了45份声明。由53名HAE专家组成的小组通过两轮Delphi流程验证了这些陈述。
    结果:ODT和STP的目标是将发作的发病率和死亡率降至最低,并防止由已知触发器引起的攻击,分别,虽然LTP的主要目标是降低利率,攻击的严重程度和持续时间。此外,开处方时,临床医生应该考虑减少不良事件,同时增加患者QoL和满意度。还指出了评估目标成就的适当工具。
    结论:我们就ODT治疗HAE-C1INH之前不清楚的方面提供建议,STP和LTP,特别关注临床和面向患者的目标。
    BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH) is a rare disease characterized by swelling episodes. It affects quality of life (QOL) and can be fatal when the upper airways are involved. Treatment is individualized, with therapeutic options including on-demand treatment (ODT) and short- and long-term prophylaxis (STP, LTP). However, available guidelines are not always clear about the selection of treatment, the goals of treatment, or how achievement of these goals is assessed.
    OBJECTIVE: To review available evidence for the management of HAE-C1INH and build a Spanish expert consensus to steer management towards a treat-to-target approach, while addressing some of the less clear aspects of the Spanish guidelines.
    METHODS: We reviewed the literature on the treat-to-target management of HAE-C1INH, focusing on treatment selection and goals and the tools available to assess whether the goals have been achieved. We discussed the literature based on clinical experience and drew up 45 statements on undefined management aspects. A panel of 53 HAE experts validated the statements through a 2-round Delphi process.
    RESULTS: The goals for ODT and STP are to minimize the morbidity and mortality of attacks and to prevent attacks caused by known triggers, respectively, while the main goal of LTP is to decrease the rate, severity, and duration of attacks. Furthermore, when prescribing, clinicians should consider the reduction in adverse effects, while increasing patient QOL and satisfaction. Appropriate instruments for assessing achievement of treatment goals are also indicated.
    CONCLUSIONS: We provide recommendations on previously unclear aspects of HAE-C1INH management with ODT, STP, and LTP, focusing on clinical and patient-oriented goals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:静脉注射阿替普酶是唯一被批准用于急性缺血性卒中(AIS)患者的溶栓治疗方法。尽管没有随机对照试验(RCT)显示替奈普酶在AIS中优于阿替普酶,替奈普酶在卒中单元中越来越多地使用标签外。本工作的目的是就Tenecteplase在AIS中的使用提供一套最新的专家共识声明。
    方法:工作组成员由法国神经血管协会选出。比较替奈普酶和阿替普酶治疗AIS的RCTs。还分析了截至2021年10月30日发表的关于替奈普酶的最新荟萃分析和现实生活经验数据。在对可用数据进行描述之后,我们试图回答关于替奈普酶在AIS中使用的后续问题:替奈普酶的剂量应该是什么?替奈普酶用于脑动脉再通的效果如何?替奈普酶的临床有效性是什么?替奈普酶的治疗安全性是什么?替奈普酶易于使用相关的益处是什么?然后提交了替奈普酶使用的专家共识声明。2021年10月,工作组被要求审查和修改手稿。2021年11月,手稿的当前版本获得批准。
    UNASSIGNED:发表了一组关于在AIS患者症状发作后4.5小时内使用替奈普酶的专家共识声明:(1)在计划使用机械血栓切除术(MT)时使用替奈普酶0.25mg/kg是合理的。(2)对于MT无法恢复的中小血管闭塞患者,替奈普酶0.25mg/kg可替代阿替普酶0.9mg/kg。(3)替奈普酶0.25mg/kg可作为阿替普酶0.9mg/kg无血管闭塞患者的替代药物。
    结论:这些专家共识声明可以提供一个框架,以指导根据AIS患者的入院特征使用替奈普酶的临床决策过程。然而,现有数据有限,需要纳入正在进行的RCT或现实生活中的登记册。
    BACKGROUND: Intravenous alteplase is the only thrombolytic treatment approved for patients with acute ischemic stroke (AIS). Although no randomized controlled trial (RCT) has shown the superiority of tenecteplase over alteplase in AIS, tenecteplase is increasingly used off-label in Stroke Units. The purpose of the present work was to provide an up-to-date set of expert consensus statements on the use of tenecteplase in AIS.
    METHODS: Members of the working group were selected by the French Neurovascular Society. RCTs comparing tenecteplase and alteplase in the treatment of AIS were reviewed. Recent meta-analysis and real-life experience data on tenecteplase published until 30th October 2021 were also analyzed. After a description of the available data, we tried to answer the subsequent questions about the use of tenecteplase in AIS: What dosage of tenecteplase should be preferred? How effective is tenecteplase for cerebral artery recanalization? What is the clinical effectiveness of tenecteplase? What is the therapeutic safety of tenecteplase? What are the benefits associated with tenecteplase ease of use? Then expert consensus statements for tenecteplase use were submitted. In October 2021 the working group was asked to review and revise the manuscript. In November 2021, the current version of the manuscript was approved.
    UNASSIGNED: A set of three expert consensus statements for the use of tenecteplase within 4.5hours of symptom onset in AIS patients were issued: (1) It is reasonable to use tenecteplase 0.25mg/kg when mechanical thrombectomy (MT) is planned. (2) Tenecteplase 0.25mg/kg can be used as an alternative to alteplase 0.9mg/kg in patients with medium- or small-vessel occlusion not retrievable with MT. (3) Tenecteplase 0.25mg/kg could be considered as an alternative to alteplase 0.9mg/kg in patients without vessel occlusion.
    CONCLUSIONS: These expert consensus statements could provide a framework to guide the clinical decision-making process for the use of tenecteplase according to admission characteristics of AIS patients. However, existing data are limited, requiring inclusions in ongoing RCTs or real-life registries.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    目的:在碳青霉烯类耐药革兰阴性菌(CRGNB)已经定植的患者中,与感染进展相关的危险因素(RFs)在很少且分散的工作中得到了解决。这项研究的目的是确定与呼吸道或直肠定植患者感染进展相关的相关RF。
    方法:进行了系统的文献综述,以确定与CRGNB呼吸道或直肠定植患者感染进展相关的RFs。然后由专家小组评估和讨论确定的RFs,以根据证据和专家经验确定相关的RFs。
    结果:共纳入CRGNB呼吸道定植8篇,CRGNB直肠定植21篇。确定19个与肺炎发展相关的RFs和44个与感染进展相关的RFs,分别。经过讨论,专家们一致认为13个RFs与呼吸道CRGNB定植后的肺炎发展相关,33个RFs与直肠CRGNB定植后的感染进展相关.呼吸道和直肠定植,与病原体和定植部位无关,将先前在ICU的住院时间和在ICU的住院时间分类为相关RF。对于CRGNB呼吸道和直肠定植的患者,先前接触抗生素治疗或先前使用碳青霉烯也是常见的相关RF。
    结论:这项研究的结果可能有助于早期识别感染发展风险较高的CRGNB定植患者,有利于有效治疗的时间和改善健康结果。
    OBJECTIVE: Risk factors (RFs) associated with infection progression in patients already colonised by carbapenem-resistant Gram-negative bacteria (CRGNB) have been addressed in few and disperse works. The aim of this study is to identify the relevant RFs associated to infection progression in patients with respiratory tract or rectal colonisation.
    METHODS: A systematic literature review was developed to identify RFs associated with infection progression in patients with CRGNB respiratory tract or rectal colonisation. Identified RFs were then evaluated and discussed by the expert panel to identify those that are relevant according to the evidence and expert\'s experience.
    RESULTS: A total of 8 articles were included for the CRGNB respiratory tract colonisation and 21 for CRGNB rectal colonisation, identifying 19 RFs associated with pneumonia development and 44 RFs associated with infection progression, respectively. After discussion, the experts agreed on 13 RFs to be associated with pneumonia development after respiratory tract CRGNB colonisation and 33 RFs to be associated with infection progression after rectal CRGNB colonisation. Respiratory tract and rectal colonisation, previous stay in the ICU and longer stay in the ICU were classified as relevant RF independently of the pathogen and site of colonisation. Previous exposure to antibiotic therapy or previous carbapenem use were also common relevant RF for patients with CRGNB respiratory tract and rectal colonisation.
    CONCLUSIONS: The results of this study may contribute to the early identification of CRGNB colonized patients at higher risk of infection development, favouring time-to-effective therapy and improving health outcomes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Review
    葡萄胎(HM)是一种异常的人类妊娠,其特征是胎盘滋养细胞过度生长和早期胚胎发育异常。在第一次这样的异常怀孕之后,女性连续磨牙妊娠的风险显着增加。迄今为止,已经证明七个母体效应基因的变体会导致复发性HM(RHM)。NLRP7是RHM的主要致病基因,并且编码含有7的NOD样受体(NLR)家族pyrin结构域,其属于与炎性病症有关的蛋白质家族。自从它的身份,所有NLRP7变体都已记录在输血中,致力于自身炎症性疾病的在线注册表(https://infevers。Umai-montpellier.fr/web/)。这里,我们回顾了已发表和未发表的与RHM相关的NLRP7隐性变异,根据美国医学遗传学学会分类对其致病性进行评分,并在患者和概念水平上概述了所有功能研究。我们还提供了32例患者的进一步变异分析和36例其他磨牙妊娠的基因型数据。这项全面的审查整合了NLRP7的已发表和未发表的数据,旨在指导遗传学家和临床医生进行变异解释。遗传咨询,以及对这种罕见疾病患者的管理。
    Hydatidiform mole (HM) is an abnormal human pregnancy characterized by excessive growth of placental trophoblasts and abnormal early embryonic development. Following a first such abnormal pregnancy, the risk for women of successive molar pregnancies significantly increases. To date variants in seven maternal-effect genes have been shown to cause recurrent HMs (RHM). NLRP7 is the major causative gene for RHM and codes for NOD-like receptor (NLR) family pyrin domain containing 7, which belongs to a family of proteins involved in inflammatory disorders. Since its identification, all NLRP7 variants have been recorded in Infevers, an online registry dedicated to autoinflammatory diseases (https://infevers.umai-montpellier.fr/web/). Here, we reviewed published and unpublished recessive NLRP7 variants associated with RHM, scored their pathogenicity according to the American College of Medical Genetics classification, and recapitulated all functional studies at the level of both the patients and the conceptions. We also provided data on further variant analyses of 32 patients and genotypes of 36 additional molar pregnancies. This comprehensive review integrates published and unpublished data on NLRP7 and aims at guiding geneticists and clinicians in variant interpretation, genetic counseling, and management of patients with this rare condition.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    Background: Neuropathic pain (NP), a severe and disruptive symptom following many diseases, normally restricts patients\' physical functions and leads to anxiety and depression. As an economical and effective therapy, exercise may be helpful in NP management. However, few guidelines and reviews focused on exercise therapy for NP associated with specific diseases. The study aimed to summarize the effectiveness and efficacy of exercise for various diseases with NP supported by evidence, describe expert recommendations for NP from different causes, and inform policymakers of the guidelines. Design: A systematic review and expert consensus. Methods: A systematic search was conducted in PubMed. We included systematic review and meta-analysis, randomized controlled trials (RCTs), which assessed patients with NP. Studies involved exercise intervention and outcome included pain intensity at least. Physiotherapy Evidence Database and the Assessment of Multiple Systematic reviews tool were used to grade the quality assessment of the included RCTs and systematic reviews, respectively. The final grades of recommendation were based on strength of evidence and a consensus discussion of results of Delphi rounds by the Delphi consensus panel including 21 experts from the Chinese Association of Rehabilitation Medicine. Results: Eight systematic reviews and 21 RCTs fulfilled all of the inclusion criteria and were included, which were used to create the 10 evidence-based consensus statements. The 10 expert recommendations regarding exercise for NP symptoms were relevant to the following 10 different diseases: spinal cord injury, stroke, multiple sclerosis, Parkinson\'s disease, cervical radiculopathy, sciatica, diabetic neuropathy, chemotherapy-induced peripheral neuropathy, HIV/AIDS, and surgery, respectively. The exercise recommended in the expert consensus involved but was not limited to muscle stretching, strengthening/resistance exercise, aerobic exercise, motor control/stabilization training and mind-body exercise (Tai Chi and yoga). Conclusions: Based on the available evidence, exercise is helpful to alleviate NP intensity. Therefore, these expert consensuses recommend that proper exercise programs can be considered as an effective alternative treatment or complementary therapy for most patients with NP. The expert consensus provided medical staff and policymakers with applicable recommendations for the formulation of exercise prescription for NP. This consensus statement will require regular updates after five-ten years.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    The use and evolution of oral anticoagulation therapies continue to advance for multiple reasons, including a growing segment of older patients with associated chronic prothrombotic illnesses including cardiovascular, pulmonary, hematologic and oncologic conditions. Correlated to this increased use of oral anticoagulants is bleeding complications associated with their use. Based on these trends, it is expected that perioperative physicians will be facing more and more of these patients requiring scheduled, urgent or emergent surgical procedures During May 2020, the American College of Cardiology updated its Expert Consensus Decision Pathway devoted to the approach of bleeding in patients on oral anticoagulants. This updated version emphasized the expanding role of the direct-acting oral anticoagulants in other conditions beyond nonvalvular atrial fibrillation, such as venous thromboembolism. Several details discussed within this most recent update are pertinent to perioperative physicians, who frequently deal with bleeding in the setting of anticoagulation. The purpose of this narrative review is to highlight and expand on these salient points because they relate to perioperative management.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Although atrial fibrillation (AF) is the most common cardiac arrhythmia, its management remains complex and depends on several variables. Over the past decade, catheter ablation has been widely used as an effective method for rhythm control in AF patients. Therefore, AF ablation has been the focus of many studies in recent years. Given the complexity of AF management and catheter ablation, several guidelines have been developed to regulate and direct management of AF patients. The European Society of Cardiology (ESC), together with the European Heart Rhythm Association (EHRA) and the European Association of Cardiothoracic Surgeons (EACTS), has been regulating the European guidelines, while the American Heart Association (AHA), along with the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS), is publishing the US guidelines. Additionally, HRS, EHRA, and the Society of Thoracic Surgeons, along with representatives from heart rhythm societies from different parts of the world, have developed an \"expert consensus statement on catheter and surgical ablation of AF.\" This article reviews and compares the most recent guidelines and consensus document on AF catheter ablation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号